Background-The goal of this study was to examine the hypothesis that a partial agonist of the adenosine A 1 receptor (A 1 AdoR) may cause a greater attenuation of catecholamine-induced ventricular arrhythmic activity than of contractility. Methods and Results-The effects of CVT-2759 and adenosine, a partial and a full agonist of the A 1 AdoR, on isoproterenol-stimulated arrhythmic activity and contractility of guinea pig isolated ventricular myocytes were determined. CVT-2759 (10 mol/L) and adenosine (10 mol/L) significantly inhibited isoproterenol-induced arrhythmic activity (aftercontraction and transient inward current) but did not reduce the amplitudes of twitch shortening and L-type Ca 2ϩ current. Increasing the concentration of the full agonist adenosine from 10 to 100 mol/L, however, caused significant attenuation of twitch shortening as well as aftercontractions, whereas increasing the concentration of the partial agonist CVT-2759 from 10 to 100 mol/L did not. CVT-2759 also significantly inhibited isoproterenol-induced spontaneous ventricular beats in isolated hearts. In contrast to adenosine, CVT-2759 neither activated adenosinesensitive K ϩ current nor shortened the duration of the atrial APD. Key Words: adenosine Ⅲ arrhythmia Ⅲ contractility Ⅲ myocytes A denosine modulates the functions of cardiac myocytes by stimulating adenosine A 1 receptors (A 1 AdoRs). 1 Adenosine activates an adenosine-sensitive K ϩ current [I K(Ado) , also known as I K(ACh) ] and thereby shortens the atrial action potential duration (APD). 2 Adenosine has little or no direct effect on ventricular myocardium of most mammalian species, including the guinea pig. 3, 4 However, adenosine antagonizes ␤-adrenergic stimulation of L-type Ca 2ϩ current [I Ca(L) ], transient inward current (I ti ), delayed afterdepolarizations (DADs), cell twitch shortening, and aftercontractions of ventricular myocytes. [3] [4] [5] Adenosine is considered a safe antiarrhythmic drug, because its action is brief. Because adenosine acts on all 4 subtypes of adenosine receptors 1 and is a full agonist, however, side effects of adenosine are common. 6 Therefore, use of adenosine is limited to a hospital setting. 6 Considering the high efficacy and the frequency of side effects of adenosine, a selective and partial agonist of the A 1 AdoR should provide advantages relative to adenosine in the treatment of cardiac arrhythmias.
Conclusions-The
A partial agonist is a low-efficacy ligand that elicits a submaximal response (compared with a full agonist) when bound to receptors at maximal occupancy. 7 In tissues with low amplification in the signal transduction path from receptor activation to functional response, a partial agonist is ineffective in causing a response. Therefore, a partial agonist causes fewer responses in the intact organism than a full agonist and is potentially a more selective drug. The N 6 heterocyclic 5Ј-modified adenosine derivative [(5-{6-[((3R)oxolan-3-yl)amino]purin-9-yl}(3S,2R,4R,5R)-3,4-dihydroxyoxolan-2-yl)methoxy]-N-methylcarboxamide (CVT-2759) is a newly synthesized partial agonist of the A 1 AdoR. 8 We hypothesized that CVT-2759 may selectively attenuate the proarrhythmic effect of a ␤-adrenoceptor agonist without significantly affecting either the contractility of ventricular myocytes or the basal electrical activity of atrial myocytes. This hypothesis is based on observations that adenosine decreases catecholamine-induced arrhythmic activity more than contractility 9 and that its potency to inhibit isoproterenol-stimulated I Ca(L) is 10-fold greater than its potency to activate I K(Ado) . 10 The hypothesis was further examined in this study. The effects of CVT-2759 on (1) isoproterenol-stimulated arrhythmic activity (DADs, I ti , and aftercontractions) and contractility [assessed by measuring twitch shortening and I Ca(L) ] of ventricular myocytes and (2) the action potentials and I K(Ado) of atrial myocytes were determined and compared with those of adenosine. The antiarrhythmic effect of CVT-2759 was also examined in isolated, perfused hearts.
Methods

Chemicals
CVT-2759 was a gift from CV Therapeutics. A stock solution of CVT-2759 (100 mmol/L) was made by dissolving the compound in DMSO. The stock solution was diluted in Tyrode's solution for use in experiments. The final content of DMSO in Tyrode's solution during experiments was no more than 0.1%. All other chemicals were purchased from Sigma.
Isolation of Hearts and Myocytes
Use of animals was in accordance with the Guide for the Care 2ϩ -free solution containing collagenase (120 U/mL) and albumin (2 mg/mL) for 20 minutes. At the end of the perfusion, the atria and ventricles were separated, minced, and gently shaken for 10 minutes in solution 3 to free single cells for study.
Measurements of Transmembrane Potential and Current
Myocytes were placed into a recording chamber and superfused with Tyrode's solution at 35°C. Drugs were applied via the superfusate. Transmembrane voltages and currents were measured with glass microelectrodes filled with solution containing (in mmol/L) 120 potassium aspartate, 20 KCl, 1 MgCl 2 , 4 Na 2 ATP, 0.1 Na 3 GTP, 10 glucose, and 10 HEPES (pH 7.2). Microelectrode resistance was 1 to 3 M⍀. An Axopatch-200 amplifier, a DigiData-1200A interface, and pCLAMP6 software (Axon Instruments) were used to perform electrophysiological measurements. The electrode capacitance, whole-cell capacitance, and series resistance were maximally compensated. The liquid junction potential was corrected. Measurements were made when the response to a drug had reached a stable maximum.
For recording I Ca(L) and I ti , myocytes were voltage-clamped at a holding potential of Ϫ40 mV to inactivate the fast Na ϩ channels. A 500-ms depolarizing pulse to 0 or ϩ20 mV was applied at a frequency of 0.5 Hz. The amplitude of I Ca(L) was measured from the zero current to the maximal inward current during the depolarizing pulse, and the amplitude of I ti was measured from the holding current to the peak inward deflection after return to the holding potential. Values of the amplitude of I Ca(L) and I ti were normalized by the whole-cell capacitance (30 to 40 pF, read from the capacitance meter of the amplifier) and expressed as pA/pF. For measurement of I K(Ado) , a 4-second ramp pulse from Ϫ120 to ϩ20 mV was applied at a frequency of 0.1 Hz. The increment of the current elicited by this voltage protocol in the presence of adenosine or CVT-2759 was determined as the amplitude of I K(Ado) . To induce action potentials, a 5-ms depolarizing pulse was applied at a frequency of 0.5 to 1 Hz. The APD was measured at 50% (APD 50 ) and 90% (APD 90 ) repolarization.
Measurement of Cell Contraction
Cell twitch shortening was elicited by the same procedure as used to induce action potentials. The amplitude of twitch shortening was determined by a video motion detector (Crescent Electronics) and was used as an index of cell contractility. 11 Action potentials and amplitude of cell twitch shortening were recorded simultaneously on a chart recorder (Gould 2200S). In this study, a twitch shortening denotes a normal systolic contraction, whereas an aftercontraction denotes a contraction that occurs during diastole and is triggered by events following the preceding normal contraction. The amplitude of twitch shortening and aftercontraction was measured from maximal cell relaxation to peak contraction and was calculated as an average of 10 consecutive events.
Ventricular Pacing and Measurement of Electrogram
Isolated hearts were perfused with warm (36Ϯ0.5°C) modified Krebs-Henseleit solution at a rate of 10 mL/min. The KrebsHenseleit solution contained (in mmol/L) 117.9 NaCl, 2.5 CaCl 2 , 4.8 KCl, 1.28 MgSO 4 , 1.2 KH 2 PO 4 , 0.5 Na 2 -EDTA, 0.14 ascorbic acid, 5.5 glucose, 2 pyruvate, and 25 NaHCO 3 , pH 7.4, gassed with 95% O 2 and 5% CO 2 . Drugs were delivered via the perfusion line. Parts of the atrial tissues, including the region of the sinoatrial node, were removed. A pacing electrode was initially placed in the atrial septum. Pacing stimuli were provided by a stimulator (Grass) as 3-ms pulses at a frequency of 3 Hz. Electrograms were recorded on a chart recorder (Gould RS3400). To facilitate ventricular pacing, a complete block of atrioventricular conduction was necessary. This was achieved by injecting a small amount (20 L) of 70% ethanol into the region of the atrioventricular node. 12 Attainment of third-degree atrioventricular block was indicated by a complete dissociation of atrial and ventricular depolarizations in the electrogram. 12 After complete atrioventricular block was produced, the pacing electrode was moved to the ventricular septum. Normal and spontaneous ventricular beats were identified as pacing-induced and non-pacinginduced ventricular depolarizations, respectively.
Statistical Analysis
Data are expressed as meanϮSEM. Values of n indicate the number of cells or hearts studied. Percentage inhibition by CVT-2759 or adenosine of the effects of isoproterenol was calculated with the formula [(isoproterenolϪCVT-2759 or adenosine)/(isoproterenolϪcontrol)]ϫ100, where isoproterenol, CVT-2759 or adenosine, and control indicate measurements obtained in the presence of isoproterenol alone, isoproterenol plus CVT-2759 or adenosine, and in the absence of drugs, respectively. The paired Student's t test was used for statistical analysis of paired data, and the 1-way repeated-measures ANOVA followed by Student-Newman-Keuls test was applied for multiple comparisons. A value of PϽ0.05 was considered statistically significant.
Results
Differential Attenuation of Twitch Shortening and Aftercontraction
Under present experimental conditions, a low concentration (15 nmol/L) of isoproterenol stimulated cell twitch shortening without inducing arrhythmic activity, whereas a high concentration (30 nmol/L) of isoproterenol induced DADs and aftercontractions as well as increasing the amplitude of twitch shortening. Therefore, by use of 15 and 30 nmol/L isoproterenol, we were able to examine the effects of CVT-2759 on twitch shortening of ventricular myocytes in the absence and presence of arrhythmic activity, respectively. Figure 1 shows the results obtained in the absence of arrhythmic activity. The amplitude of twitch shortening was increased by isoproterenol (15 nmol/L) from 2.6Ϯ0.3 to 5.8Ϯ0.7 m (nϭ9, PϽ0.05). Neither DADs nor aftercontractions were observed. CVT-2759 (10 mol/L) attenuated isoproterenol-stimulated twitch shortenings by 27Ϯ2%, decreasing the amplitude of twitch shortening to 4.9Ϯ0.5 m (PϽ0.05). This effect of CVT-2759 (and all other effects of CVT-2759 observed in the present study) was reversed on washout of drug. CVT-2759 (10 mol/L) alone had no effect on the resting membrane potential (Ϫ84Ϯ2 versus Ϫ84Ϯ1 mV, nϭ7). To determine whether CVT-2759 inhibits twitch shortening when applied at a higher concentration, some myocytes (8 of 14) were further exposed to 100 mol/L CVT-2759 ( Figure 3 
Lack of Effect on Atrial Myocytes
CVT-2759 (10 mol/L) did not significantly shorten the APD of atrial myocytes ( Figure 6, A Application of a ramp voltage-clamp pulse from Ϫ120 to ϩ20 mV to atrial myocytes in the absence of drug elicited a background inward-rectifying K ϩ current (I K1 ). 15 Because the current-voltage relationships for I K(Ado) and I K1 are similar, activation of I K(Ado) is determined as an increase of the current in the presence of CVT-2759 or adenosine. The currents recorded in the absence of drug and in the presence of CVT-2759 (10 mol/L) were not significantly different ( Figure 6C ). The amplitude of the current in the presence of adenosine (10 mol/L), however, was significantly greater than the amplitude of the background current ( Figure 6C ), indicating an activation of I K(Ado) . When measured at 0 mV, the amplitudes (nϭ4) of the background current and the currents in the presence of CVT-2759 and adenosine were 183Ϯ75, 200Ϯ70 (PϾ0.05 versus control), and 603Ϯ75 (PϽ0.05 versus control) pA, respectively ( Figure 5D ).
Inhibition of Spontaneous Ventricular Beats
The antiarrhythmic effect of CVT-2759 was further tested in isolated hearts by determining the effect of CVT-2759 on isoproterenol-induced spontaneous ventricular beats ( Figure  6 ). Spontaneous ventricular beats were observed only in the presence of isoproterenol (30 nmol/L). CVT-2759 (10 mol/L) alone had no effect on paced beats (not shown) but significantly reduced isoproterenol-induced spontaneous beats from 118Ϯ12 to 64Ϯ16 bpm (nϭ6, PϽ0.05).
Discussion
The results of this study confirm the hypothesis that the partial A 1 AdoR agonist CVT-2759 can selectively attenuate the proarrhythmic effect of isoproterenol to induce aftercontractions, DADs, and I ti without significantly reducing the contractility of ventricular myocytes and without affecting the electrical activity of atrial myocytes.
Potential Mechanism for the Differential Anti-␤-Adrenergic Actions
The differential anti-␤-adrenergic actions of CVT-2759 may involve the regulation of intracellular Ca 2ϩ release. Release of Ca 2ϩ from the SR during diastole is thought to be a common mechanistic step in the induction of aftercontractions and I ti . 14 Because CVT-2759 inhibits both aftercontractions and I ti , it is likely that CVT-2759 attenuates isoproterenol-stimulated diastolic Ca 2ϩ release. Consistent with this assumption, ryanodine (100 nmol/L), an inhibitor of SR Ca 2ϩ release, 16 caused an inhibitory effect similar to that of CVT-2759 on isoproterenol-stimulated DADs and aftercontractions. 9 Diastolic Ca 2ϩ release from the SR has been shown to cause a reduction of cell twitch shortening. 17, 18 We found that the amplitude of twitch shortening following an aftercontraction was smaller than that without a preceding aftercontraction (Figure 3, A and B) . There is evidence that spontaneous Ca 2ϩ release may cause a refractory period in Ca 2ϩ release from the SR, 19 and Ca 2ϩ released from the SR may inactivate L-type Ca 2ϩ channels. 20 These observations suggest that diastolic Ca 2ϩ release may reduce both intracellular Ca 2ϩ release and extracellular Ca 2ϩ entry during systole and thereby decrease the amplitude of cell twitch shortening. Thus, reduction by ryanodine of the diastolic Ca 2ϩ release resulted in an increase of the twitch shortening. 17, 18 The underlying mechanism by which CVT-2759 attenuated isoproterenol-induced diastolic Ca 2ϩ release is most likely inhibition of isoproterenolstimulated cAMP formation and protein phosphorylation. 5, 13 Although the mechanisms of the actions of CVT-2759 and ryanodine are not the same, inhibition by CVT-2759 of diastolic Ca 2ϩ release could also be expected to facilitate twitch shortening and I Ca(L) . Thus, the moderate, direct inhibitory effect of CVT-2759 on isoproterenol-stimulated twitch shortening ( Figure 1 ) and I Ca(L) (Figure 4 ) may be well compensated by the facilitatory effect of a reduction of diastolic Ca 2ϩ release on twitch shortening and I Ca(L) . Although an inhibition of diastolic Ca 2ϩ release from the SR alone can explain the selective anti-␤-adrenergic actions of CVT-2759, a direct inhibition of the sodium-calcium exchange current cannot be ruled out as a potential mechanism to explain the attenuation by CVT-2759 of isoproterenol-induced I ti . 21 
Comparison of Actions of CVT-2759 and Adenosine
The actions of CVT-2759 were similar to those of adenosine at a low concentration. The difference was that when their concentrations were increased from 10 to 100 mol/L, adenosine further attenuated the twitch shortening, whereas CVT-2759 did not (Figure 3) . In other words, at a high concentration, the selectivity of action of adenosine decreases, whereas the selectivity of action of CVT-2759 remains. This is because the partial agonist CVT-2759 causes only a submaximal response 7, 8 compared with the full agonist adenosine. Although it is a low-efficacy agonist, however, CVT-2759 significantly attenuated isoproterenol-stimulated ventricular arrhythmic activity in intact hearts ( Figure 7 ) as well as in isolated cells. These results suggest that CVT-2759 can be an effective antiarrhythmic drug.
Lack of Effect on Atrial Myocytes
Another major difference between the actions of CVT-2759 and adenosine was that adenosine activated I K(Ado) and shortened the atrial APD, whereas CVT-2759 had little effect on atrial myocytes (Figure 6 ). Thus, CVT-2759 is a more selective antiarrhythmic drug than adenosine, not only because it causes less inhibition of twitch shortening of ventricular myocytes but also because it does not affect the action potentials of atrial myocytes. The lack of effect of CVT-2759 on atrial action potentials is probably due to a lack of effect of the drug on I K(Ado) . The differential effects of CVT-2759 on I K(Ado) and on isoproterenol-stimulated I Ca(L) and I ti were expected and can be explained by the receptor reserve theory. That is, it has been shown that a higher occupancy of A 1 AdoRs is required for activation of I K(Ado) than for antagonism of ␤-adrenergic stimulation. 10 Thus, the full agonist adenosine is more potent to inhibit isoproterenol-stimulated I Ca(L) than to activate I K(Ado) , and a partial agonist of the A 1 AdoR may attenuate ␤-adrenergic stimulation without activating I K(Ado) .
Results of the present study demonstrate that the partial agonist CVT-2759 has greater selectivity than the full agonist adenosine to antagonize the proarrhythmic effect of catecholamines on ventricular myocytes. Furthermore, the present results illustrate the pharmacological concept that selectivity of action is greater for partial than for full agonists of a given receptor. 22 A partial agonist of the A 1 AdoR, such as CVT-2759, may be a promising candidate in the search for an adenosine analogue that will provide effective and specific treatment of cardiac arrhythmias. 
